Modular Medical Inc. (NASDAQ: MODD) announced it has regained compliance with Nasdaq's minimum bid price requirement after receiving notification from the exchange.

The company received a letter from Nasdaq Stock Market LLC stating that as of April 14, 2026, Modular Medical's common stock maintained a closing bid price above $1.00 for 10 consecutive trading days. This satisfies Nasdaq Marketplace Rule 5550(a)(2), and the exchange considers the compliance matter closed.

Modular Medical develops insulin delivery technology and is in the development stage for medical devices. The company was founded by Paul DiPerna, who previously founded Tandem Diabetes in 2005 and designed its t:slim insulin pump.

The information was disclosed in a company press release.